Serious adverse events experienced by patients with chronic heart failure taking spironolactone
about
A critical evaluation of the NICE guidelines for post-myocardial infarction prophylaxis. National Institute for Clinical ExcellenceEffects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failureInteraction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.Effects of low-dose spironolactone combined with irbesartan on cardiac hypertrophy induced by pressure overload in rats.Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatmentTolerability of spironolactone in patients with chronic heart failure -- a cautionary messageThe Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled TrialNew strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.What is the risk of hyperkalaemia in heart failure?The safety of spironolactone treatment in patients with heart failure.Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians.Physician opinions on the implementation of the SIGN guideline for heart failure.Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker.Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.
P2860
Q28192295-C301FB3B-C280-4522-8AD2-E813977D5B33Q28212766-FD11A8D9-AD8A-4035-88FA-60D8FD6D0B4AQ33815762-4DAFD5A5-E371-401E-9C84-84B311CEDE65Q34978812-D3E96BF8-CB0F-4A0D-A97B-433BF611970FQ35582571-A984B007-10C3-4F5D-B8A0-07AFBEF399ACQ35826462-0777726C-EED0-44A2-A7F9-AA67A4D5F8C9Q36025666-875DA8D9-9F15-4545-9D7B-B5DD03F02E22Q36191021-5708140C-3821-4EF0-9492-E78732E195A7Q36792952-AEBF547E-30E4-49D8-94E1-2926EDCD865DQ37902667-6C8DA9E5-1CC3-4F38-9EB7-EE3909435B8EQ44545200-8D8B686D-0BE0-401B-B831-15F4840EE328Q44551644-75A9AA9A-A105-407E-98B0-0E24584F9D57Q44793743-385EC98E-B784-4677-BAB5-97B8C649B7A6Q48358493-98C754D5-1D65-47F3-B95D-E962C3086401Q49349456-750BC090-DE32-4896-B39D-056334236CCC
P2860
Serious adverse events experienced by patients with chronic heart failure taking spironolactone
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Serious adverse events experie ...... failure taking spironolactone
@ast
Serious adverse events experie ...... failure taking spironolactone
@en
Serious adverse events experie ...... failure taking spironolactone
@nl
type
label
Serious adverse events experie ...... failure taking spironolactone
@ast
Serious adverse events experie ...... failure taking spironolactone
@en
Serious adverse events experie ...... failure taking spironolactone
@nl
prefLabel
Serious adverse events experie ...... failure taking spironolactone
@ast
Serious adverse events experie ...... failure taking spironolactone
@en
Serious adverse events experie ...... failure taking spironolactone
@nl
P2860
P356
P1433
P1476
Serious adverse events experie ...... failure taking spironolactone
@en
P2093
P2860
P356
10.1136/HEART.85.4.E8
P407
P577
2001-04-01T00:00:00Z